Gyre Therapeutics, Inc. Amortization of Intangible Assets
Gyre Therapeutics, Inc. (GYRE) reported Amortization of Intangible Assets of $179.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-07
- Gyre Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $179.00K, a 7.19% increase year-over-year.
- Gyre Therapeutics, Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $175.00K, a 161.19% increase year-over-year.
- Gyre Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $172.00K, a 1333.33% increase year-over-year.
- Gyre Therapeutics, Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $170.00K, a 1600.00% increase year-over-year.
- Gyre Therapeutics, Inc. amortization of intangible assets for fiscal 2025 was $576.00K, a 1415.79% increase from fiscal 2024.
- Gyre Therapeutics, Inc. amortization of intangible assets for fiscal 2024 was $38.00K, a 62.00% decline from fiscal 2023.
- Gyre Therapeutics, Inc. amortization of intangible assets for fiscal 2023 was $100.00K, a 50.00% decline from fiscal 2022.
- Gyre Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $200.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $179.00K 10-Q · filed 2026-08-07 | $354.00K 10-Q · filed 2026-08-07 | $526.00K derived: sum of 3 quarters · filed 2026-08-07 | $696.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $175.00K 10-Q · filed 2026-05-08 | $347.00K derived: sum of 2 quarters · filed 2026-05-08 | $517.00K derived: sum of 3 quarters · filed 2026-05-08 | $684.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $342.00K derived: sum of 2 quarters · filed 2026-03-13 | $509.00K derived: sum of 3 quarters · filed 2026-08-07 | $576.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $170.00K 10-Q · filed 2025-11-07 | $337.00K derived: sum of 2 quarters · filed 2026-08-07 | $404.00K 10-Q · filed 2025-11-07 | $416.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $167.00K 10-Q · filed 2026-08-07 | $234.00K 10-Q · filed 2026-08-07 | $246.00K derived: sum of 3 quarters · filed 2026-08-07 | $256.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $67.00K 10-Q · filed 2026-05-08 | $79.00K derived: sum of 2 quarters · filed 2026-05-08 | $89.00K derived: sum of 3 quarters · filed 2026-05-08 | $97.50K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $22.00K derived: sum of 2 quarters · filed 2026-03-13 | $30.50K derived: sum of 3 quarters · filed 2026-03-13 | $38.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $10.00K 10-Q · filed 2025-11-07 | $18.50K derived: sum of 2 quarters · filed 2025-11-07 | $26.00K 10-Q · filed 2025-11-07 | $111.50K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $8.50K 10-Q · filed 2025-08-11 | $16.00K 10-Q · filed 2025-08-11 | $101.50K derived: sum of 3 quarters · filed 2025-08-11 | $115.50K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-09 | $93.00K derived: sum of 2 quarters · filed 2025-05-09 | $107.00K derived: sum of 3 quarters · filed 2025-05-09 | $155.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $7.00K derived: sum of 2 quarters · filed 2025-03-17 | $55.00K derived: sum of 3 quarters · filed 2025-03-17 | $100.00K 10-K · filed 2025-03-17 |
| 2023-09-30 | $14.00K 10-Q · filed 2024-11-13 | $62.00K derived: sum of 2 quarters · filed 2024-11-13 | $107.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $48.00K 10-Q · filed 2024-08-13 | $93.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $45.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $200.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |